MA44547B1 - Anticorps anti-pd-1,procédé de leur production et de leur utilisation - Google Patents
Anticorps anti-pd-1,procédé de leur production et de leur utilisationInfo
- Publication number
- MA44547B1 MA44547B1 MA44547A MA44547A MA44547B1 MA 44547 B1 MA44547 B1 MA 44547B1 MA 44547 A MA44547 A MA 44547A MA 44547 A MA44547 A MA 44547A MA 44547 B1 MA44547 B1 MA 44547B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- relates
- oncology
- human
- present
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2016128487A RU2656181C1 (ru) | 2016-07-13 | 2016-07-13 | Анти-pd-1-антитела, способ их получения и способ применения |
| PCT/RU2017/050056 WO2018013017A1 (ru) | 2016-07-13 | 2017-07-04 | Анти-pd-1-антитела, способ их получения и способ применения |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA44547A1 MA44547A1 (fr) | 2020-01-31 |
| MA44547B1 true MA44547B1 (fr) | 2021-09-30 |
Family
ID=60953256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA44547A MA44547B1 (fr) | 2016-07-13 | 2017-07-04 | Anticorps anti-pd-1,procédé de leur production et de leur utilisation |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11136408B2 (enExample) |
| EP (1) | EP3486257A4 (enExample) |
| JP (1) | JP6993992B2 (enExample) |
| KR (1) | KR102482710B1 (enExample) |
| CN (1) | CN110023335B (enExample) |
| BR (1) | BR112019000436A2 (enExample) |
| CA (1) | CA3021372A1 (enExample) |
| CL (1) | CL2018003407A1 (enExample) |
| CO (1) | CO2019001246A2 (enExample) |
| CR (1) | CR20190009A (enExample) |
| EC (1) | ECSP19010852A (enExample) |
| JO (1) | JOP20190002A1 (enExample) |
| MA (1) | MA44547B1 (enExample) |
| MX (1) | MX2018014937A (enExample) |
| NI (1) | NI201900002A (enExample) |
| NZ (1) | NZ750221A (enExample) |
| PE (1) | PE20190450A1 (enExample) |
| PH (1) | PH12018550179A1 (enExample) |
| RU (1) | RU2656181C1 (enExample) |
| WO (1) | WO2018013017A1 (enExample) |
| ZA (1) | ZA201900792B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201911035QA (en) | 2015-11-18 | 2020-01-30 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
| WO2018133842A1 (zh) | 2017-01-20 | 2018-07-26 | 大有华夏生物医药集团有限公司 | 人程序性死亡受体pd-1的单克隆抗体及其片段 |
| BR112019021520A2 (pt) | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune |
| MX2019014577A (es) | 2017-06-05 | 2020-07-29 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y metodos de uso. |
| CR20200099A (es) | 2017-08-03 | 2020-07-24 | Amgen Inc | Muteínas de interleucina 21 y métodos de tratamiento |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| WO2019148410A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1 antibodies |
| JP7519985B2 (ja) | 2018-07-19 | 2024-07-22 | タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド | 抗ｐｄ－１抗体、投薬量、およびその使用 |
| CN109652453B (zh) * | 2018-12-29 | 2021-04-06 | 杭州科兴生物科技有限公司 | 一种基于pd-1/pdl-1阻断功能及生物效应的抗癌药物快速筛选方法 |
| JP2022534889A (ja) | 2019-05-24 | 2022-08-04 | ファイザー・インコーポレイテッド | Ｃｄｋ阻害剤を使用した組合せ療法 |
| JP7680967B2 (ja) * | 2019-06-14 | 2025-05-21 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｐｄ－１に対する抗体およびその使用方法 |
| CN111420049A (zh) | 2019-08-22 | 2020-07-17 | Biocad股份公司 | 抗-pd1抗体prolgolimab的水性药物组合物及其应用 |
| RU2753282C2 (ru) * | 2019-09-19 | 2021-08-12 | Закрытое Акционерное Общество "Биокад" | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
| MX2022010515A (es) | 2020-02-28 | 2022-11-14 | Tallac Therapeutics Inc | Conjugacion mediada por transglutaminasa. |
| MX2022014974A (es) | 2020-05-26 | 2023-01-11 | Boehringer Ingelheim Int | Anticuerpos anti-pd-1. |
| WO2022118197A1 (en) | 2020-12-02 | 2022-06-09 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
| CN116782937A (zh) * | 2020-12-10 | 2023-09-19 | 优特力克斯有限公司 | 抗pd-1抗体及其用途 |
| KR20230163503A (ko) * | 2021-03-31 | 2023-11-30 | 메뤼스 엔.페. | 신규한 pd-1 결합 도메인 |
| MA62924A1 (fr) | 2021-04-08 | 2024-03-29 | Biocad Joint Stock Co | Traitement de néoplasies malignes à l'aide d'une combinaison d'anticorps anti-pd-1 |
| TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
| EP4598960A1 (en) * | 2022-10-05 | 2025-08-13 | Chulalongkorn University | Monoclonal antibodies against human programmed cell death protein 1 (pd-1) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1896582A4 (en) * | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| WO2008156712A1 (en) * | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
| US8062852B2 (en) * | 2007-10-01 | 2011-11-22 | The Children's Hospital And Regional Medical Center | Detection and treatment of autoimmune disorders |
| MX343747B (es) * | 2009-11-24 | 2016-11-22 | Medimmune Ltd | Agentes de union diana contra b7-h1. |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| WO2011110604A1 (en) | 2010-03-11 | 2011-09-15 | Ucb Pharma, S.A. | Pd-1 antibody |
| EP3590965A1 (en) * | 2011-03-29 | 2020-01-08 | Roche Glycart AG | Antibody fc variants |
| ES2845609T3 (es) * | 2013-05-02 | 2021-07-27 | Anaptysbio Inc | Anticuerpos dirigidos contra muerte programada-1 (PD-1) |
| EA034666B1 (ru) * | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| PL3177640T3 (pl) * | 2014-08-08 | 2020-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania |
| GB201419084D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-PD-1 antibodies |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
-
2016
- 2016-07-13 RU RU2016128487A patent/RU2656181C1/ru active
-
2017
- 2017-06-16 JO JOP/2019/0002A patent/JOP20190002A1/ar unknown
- 2017-07-04 KR KR1020197003862A patent/KR102482710B1/ko active Active
- 2017-07-04 EP EP17828049.1A patent/EP3486257A4/en active Pending
- 2017-07-04 WO PCT/RU2017/050056 patent/WO2018013017A1/ru not_active Ceased
- 2017-07-04 CR CR20190009A patent/CR20190009A/es unknown
- 2017-07-04 US US16/095,800 patent/US11136408B2/en active Active
- 2017-07-04 PE PE2019000027A patent/PE20190450A1/es unknown
- 2017-07-04 MX MX2018014937A patent/MX2018014937A/es unknown
- 2017-07-04 CA CA3021372A patent/CA3021372A1/en active Pending
- 2017-07-04 JP JP2018567611A patent/JP6993992B2/ja active Active
- 2017-07-04 CN CN201780055794.3A patent/CN110023335B/zh active Active
- 2017-07-04 BR BR112019000436A patent/BR112019000436A2/pt unknown
- 2017-07-04 NZ NZ750221A patent/NZ750221A/en unknown
- 2017-07-04 MA MA44547A patent/MA44547B1/fr unknown
-
2018
- 2018-10-26 PH PH12018550179A patent/PH12018550179A1/en unknown
- 2018-11-29 CL CL2018003407A patent/CL2018003407A1/es unknown
-
2019
- 2019-01-08 NI NI201900002A patent/NI201900002A/es unknown
- 2019-02-07 ZA ZA2019/00792A patent/ZA201900792B/en unknown
- 2019-02-12 CO CONC2019/0001246A patent/CO2019001246A2/es unknown
- 2019-02-13 EC ECSENADI201910852A patent/ECSP19010852A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110023335A (zh) | 2019-07-16 |
| AU2017297138A1 (en) | 2019-02-14 |
| EP3486257A1 (en) | 2019-05-22 |
| RU2656181C1 (ru) | 2018-05-31 |
| US20190127478A1 (en) | 2019-05-02 |
| PH12018550179A1 (en) | 2019-03-11 |
| EP3486257A4 (en) | 2020-03-04 |
| CA3021372A1 (en) | 2018-01-18 |
| JP6993992B2 (ja) | 2022-01-14 |
| CO2019001246A2 (es) | 2019-02-19 |
| US11136408B2 (en) | 2021-10-05 |
| WO2018013017A1 (ru) | 2018-01-18 |
| KR102482710B1 (ko) | 2023-01-02 |
| NI201900002A (es) | 2019-06-11 |
| ECSP19010852A (es) | 2019-06-30 |
| MA44547A1 (fr) | 2020-01-31 |
| BR112019000436A2 (pt) | 2019-10-01 |
| JOP20190002A1 (ar) | 2019-01-10 |
| CL2018003407A1 (es) | 2019-03-29 |
| AU2017297138A2 (en) | 2019-02-21 |
| KR20190029641A (ko) | 2019-03-20 |
| CR20190009A (es) | 2019-06-05 |
| CN110023335B (zh) | 2024-05-17 |
| MX2018014937A (es) | 2019-05-16 |
| NZ750221A (en) | 2022-09-30 |
| PE20190450A1 (es) | 2019-03-29 |
| JP2019527543A (ja) | 2019-10-03 |
| ZA201900792B (en) | 2020-03-25 |
| AU2017297138A8 (en) | 2019-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44547B1 (fr) | Anticorps anti-pd-1,procédé de leur production et de leur utilisation | |
| MA49599B1 (fr) | Anticorps spécifiques à cd47 et pd-l1 | |
| EA201990781A9 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| EA201990171A1 (ru) | Биспецифичное антитело против egfr и против cd3 и его применения | |
| PH12022550509A1 (en) | Anti-cd73 antibodies | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| JOP20200161A1 (ar) | أجسام مضادة أحادية النسيلة وطرق استخدامها | |
| MA42622B1 (fr) | Agents de liaison à tigit et leurs utilisations | |
| EA201992755A1 (ru) | Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4) | |
| SG10201908259WA (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonsits | |
| MX2022007035A (es) | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp. | |
| MA40913A (fr) | Conjugués anticorps-médicament | |
| EA202290054A1 (ru) | Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3 | |
| MA37761A1 (fr) | Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations | |
| MA47221A1 (fr) | Anticorps monoclonal à pd-l1 | |
| MY206214A (en) | Monoclonal antibodies that bind specifically to human trbv9 | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| PH12021550322A1 (en) | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof | |
| MA49607B2 (fr) | ANTICORPS MONOCLONAL POUR IL-5Rα | |
| MX2022004058A (es) | Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo. | |
| TH1901000154A (th) | แอนติบอดีต้าน pd-1, วิธีการผลิตและวิธีการใช้ของสิ่งดังกล่าว | |
| EA202091738A1 (ru) | Способы лечения рака антителами-антагонистами к pd-1 | |
| EA202092640A1 (ru) | Способы и композиции для лечения хронической крапивницы | |
| EA202090449A1 (ru) | Связывающие агенты, связывающие pd-l1 и cd137, и их применение |